Storia in 2 fonti

Pharma deal activity hits four-quarter low, but mega Sun Pharma acquisition drives value

India's pharma and healthcare sector recorded 65 deals worth $13.9 billion in Q2 CY2026, with volumes falling 17% quarter-on-quarter to a four-quarter low, Grant Thornton Bharat said. Sun Pharma's $11.8 billion Organon acquisition drove deal values, while investors continued backing AI-led healthcare, genomics, oncology and precision medicine ventures.

Raccontata da

economictimes.indiatimes.com

timesofindia.indiatimes.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

economictimes.indiatimes.comStai leggendo12 h fa

Pharma deal activity hits four-quarter low, but mega Sun Pharma acquisition drives value

Sun Pharma acquired Organon for $11.8B, India's largest pharma export deal, driving Q2 dealflow to $13.9B amid volume declines. M&A focus on AI-diagnostics, genomics and oncology reshapes healthcare tech vendor strategy and IT infrastructure investment priorities globally.

originale

timesofindia.indiatimes.com7 h fa

Deal activity cools in pharma, healthcare in Q2

Sun Pharma acquires Organon (US) for $11.8B, largest Indian pharma overseas deal; Q2 M&A $13.2B, volumes down 17% but values resilient. Consolidation reflects investor appetite for innovation healthcare (AI diagnostics, genomics, oncology); signals surging demand for AI-healthcare infrastructure.

Timeline cronologica

venerdì 24 luglio 2026·economictimes.indiatimes.com
Pharma deal activity hits four-quarter low, but mega Sun Pharma acquisition drives value
India's pharma and healthcare sector recorded 65 deals worth $13.9 billion in Q2 CY2026, with volumes falling 17% quarter-on-quarter to a four-quarter low, Grant Thornton Bharat…
venerdì 24 luglio 2026·timesofindia.indiatimes.com
Deal activity cools in pharma, healthcare in Q2
NEW DELHI: The domestic pharma and healthcare sector recorded 65 transactions totalling nearly $14 billion in Q2 2026, with deal activity moderating to a four-quarter low as…